Many people have reported pain at the injection site after receiving a shot of COVID-19 vaccine, but intense and prolonged pain after injection could be caused by shoulder injury related to vaccine administration (SIRVA), a Taipei City Hospital doctor said.
Chen Hsin-chang (陳信彰), an orthopedist at the hospital’s Heping Fuyou Branch, said that discomfort at the injection site is one of the most common side effects of receiving a COVID-19 vaccine, which include redness, swelling, heat, pain and limited range of motion.
The discomfort is usually mild for most vaccine recipients, but a few might feel intense pain at the injection site to the extent that they need to take a day or two off work to recover, he said.
SIRVA usually occurs immediately after vaccine injection, Chen said.
Statistics suggests that about 90 percent had symptoms of SIRVA within 24 hours after vaccination, but rarely three days after receiving a jab, Chen said, adding that bacterial infection should be ruled out when diagnosing it.
SIRVA manifestations include shoulder bursitis, tendonitis, rotator cuff tear and adhesive capsulitis, also known as frozen shoulder, he said.
SIRVA might occur when a vaccine is injected too high or too deep in the shoulder, injuring the subacromial bursa or other nonmuscular tissues, rather than given in the deltoid muscle, he said.
In addition to avoiding giving the injection too high in the shoulder, healthcare providers can ask the vaccine recipient to bend their arm at the elbow, away from the body and resting on the hip, to avoid having the subacromial bursitis, tendon and articular capsule under the acromion getting injected, he said.
Asked whether people should avoid pressing and massaging the injection site with their fingers, Chen said studies on SIRVA did not discuss if pressing and massaging the injection site after vaccination is recommended, but he thinks that massaging the injection site does not affect muscle tissue.
Alain Robert, known as the "French Spider-Man," praised Alex Honnold as exceptionally well-prepared after the US climber completed a free solo ascent of Taipei 101 yesterday. Robert said Honnold's ascent of the 508m-tall skyscraper in just more than one-and-a-half hours without using safety ropes or equipment was a remarkable achievement. "This is my life," he said in an interview conducted in French, adding that he liked the feeling of being "on the edge of danger." The 63-year-old Frenchman climbed Taipei 101 using ropes in December 2004, taking about four hours to reach the top. On a one-to-10 scale of difficulty, Robert said Taipei 101
Nipah virus infection is to be officially listed as a category 5 notifiable infectious disease in Taiwan in March, while clinical treatment guidelines are being formulated, the Centers for Disease Control (CDC) said yesterday. With Nipah infections being reported in other countries and considering its relatively high fatality rate, the centers on Jan. 16 announced that it would be listed as a notifiable infectious disease to bolster the nation’s systematic early warning system and increase public awareness, the CDC said. Bangladesh reported four fatal cases last year in separate districts, with three linked to raw date palm sap consumption, CDC Epidemic Intelligence
US climber Alex Honnold left Taiwan this morning a day after completing a free-solo ascent of Taipei 101, a feat that drew cheers from onlookers and gained widespread international attention. Honnold yesterday scaled the 101-story skyscraper without a rope or safety harness. The climb — the highest urban free-solo ascent ever attempted — took just more than 90 minutes and was streamed live on Netflix. It was covered by major international news outlets including CNN, the New York Times, the Guardian and the Wall Street Journal. As Honnold prepared to leave Taiwan today, he attracted a crowd when he and his wife, Sanni,
Taiwanese and US defense groups are collaborating to introduce deployable, semi-autonomous manufacturing systems for drones and components in a boost to the nation’s supply chain resilience. Taiwan’s G-Tech Optroelectronics Corp subsidiary GTOC and the US’ Aerkomm Inc on Friday announced an agreement with fellow US-based Firestorm Lab to adopt the latter’s xCell, a technology featuring 3D printers fitted in 6.1m container units. The systems enable aerial platforms and parts to be produced in high volumes from dispersed nodes capable of rapid redeployment, to minimize the risk of enemy strikes and to meet field requirements, they said. Firestorm chief technology officer Ian Muceus said
RSS